Synthetic Peptides Induce Human Colorectal Cancer Cell Death via Proapoptotic Pathways
Felipe P Mesquita1, Francisco L de Oliveira1, Emerson L da Silva1
1Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE 60430-275, Brazil.
Abstract:
Cancer resistance to drugs and chemotherapy is a problem faced by public health systems worldwide. Repositioning antimicrobial peptides could be an efficient strategy to overcome that problem. This study aimed at repurposing antimicrobial peptides PepGAT and PepKAA for cancer treatment. After screening against several cancers, PepGAT and PepKAA presented IC50 values of 125.42 and 40.51 μM at 72 h toward colorectal cancer (CRC) cells. The mechanisms of action revealed that both peptides induced cell cycle arrest in G2/M and drove HCT-116 cells to death by triggering apoptosis. qPCR analysis revealed that peptides modulated gene expression in apoptosis, corroborating the data from caspase 3/7 and flow cytometry experiments. Yet, peptides induced ROS overaccumulation and increased membrane permeabilization, pore formation, and loss of internal content, leading to death. Additionally, peptides were able to inhibit cell invasion. Previous studies from the same group attested to no toxicity to normal human cells. Thus, PepGAT and PepKAA have great potential as anticancer molecules.
Insights
Antimicrobial peptides PepGAT and PepKAA show promise in treating colorectal cancer (CRC). These peptides induce cancer cell death and inhibit invasion without harming normal cells, offering a potential new strategy against drug-resistant cancers.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Drug and chemotherapy resistance in cancer presents a significant global health challenge.
- Repurposing antimicrobial peptides (AMPs) offers a promising strategy to overcome cancer resistance.
- Existing research suggests AMPs possess cytotoxic effects against cancer cells.
Purpose of the Study:
- To investigate the potential of repurposing antimicrobial peptides PepGAT and PepKAA for cancer treatment.
- To evaluate the efficacy and mechanisms of action of PepGAT and PepKAA against colorectal cancer (CRC) cells.
- To assess the safety profile of these peptides in normal human cells.
Main Methods:
- Screening of PepGAT and PepKAA against various cancer cell lines.
- Determination of IC50 values for colorectal cancer (CRC) cells.
- Analysis of cell cycle progression, apoptosis induction (caspase 3/7 assays, flow cytometry, qPCR), reactive oxygen species (ROS) production, and membrane permeabilization.
- Assessment of cell invasion inhibition.
- Evaluation of cytotoxicity in normal human cells.
Main Results:
- PepGAT and PepKAA demonstrated significant cytotoxicity against CRC cells with IC50 values of 125.42 μM and 40.51 μM, respectively.
- Both peptides induced G2/M cell cycle arrest and apoptosis in HCT-116 cells, confirmed by gene expression modulation and biochemical assays.
- Peptides caused ROS overaccumulation, increased membrane permeabilization, and inhibited cell invasion.
- Previous studies confirmed no toxicity to normal human cells.
Conclusions:
- Antimicrobial peptides PepGAT and PepKAA exhibit potent anticancer activity against colorectal cancer.
- The mechanism involves induction of apoptosis, cell cycle arrest, ROS generation, and membrane damage.
- These peptides show potential as novel therapeutic agents for cancer treatment, particularly in overcoming drug resistance, with a favorable safety profile.
More Related Videos
Related Concept Videos
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
Apoptosis
Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
Caspases
Phagocytosis of Apoptotic Cells
Normal cells contain receptors that prevent them from being recognized...


